Nimbus hopes to strike thrice
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Asco-GI 2023 – zolbetuximab opens up a stomach cancer niche
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.
Big caps bounce back for biopharma
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
Three Tigit players look to surprise in 2023
But two have already disappointed, and the third has shown little to suggest a positive outcome.
